Please join us on Tuesday, February 18, for an educational webinar hosted by Dr. Melinda Shelby, Senior Scientist, Sports, Aegis Sciences Corporation. Dr. Shelby will discuss trends in Novel Psychoactive Substance detection in 2024.
Since 2021, Aegis has provided industry-leading testing for numerous classes of novel psychoactive substances (NPS) to allow clinicians the opportunity to evaluate their patients’ substance use more completely. Without advanced testing, use of these substances by individuals may go undetected, which can interfere with prescribed therapy and could result in severe adverse events.
Each year we offer a review of the NPS analytes detected in Aegis healthcare samples when testing was ordered so clinicians can use this information to inform harm reduction and overdose prevention strategies.
Objectives Include:
- Identify trends in NPS detection in 2024
- Review various classes of NPS
- Highlight the most prevalent NPS identified in 2024 for each NPS class
